The UAE's Ministry of Health and Prevention (MOHAP) has announced the official registration of the Beijing Institute of Biological Product's inactivated COVID-19 vaccine.
The decision was made after the Department of Health Abu Dhabi reviewed Sinopharm CNBG's interim analysis of its phase III trials (which included 31,000 volunteers in the UAE alone), showing 86% efficacy against the coronavirus.
According to the analysis, the drug has a 99% seroconversion rate and 100% effectiveness in preventing moderate and severe cases of the disease.
The UAE has been conducting phase 3 clinical trials of the Sinopharm vaccine since July and in September the authorities approved its emergency use in the country. At the same time, trials of the drug continue in Egypt, Jordan, and Bahrain.